A Phase 1 Placebo-Controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Escalating Oral Doses Of PF-04620110 In Otherwise Healthy Overweight And Obese Subjects.
Phase of Trial: Phase I
Latest Information Update: 22 Jul 2009
At a glance
- Drugs PF 4620110 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 22 Jul 2009 Actual initiation date changed from Dec 2008 to Nov 2008 as reported by ClinicalTrials.gov.
- 22 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 May 2009 Planned end date changed from Feb 2009 to Jun 2009 as reported by ClinicalTrials.gov.